[go: up one dir, main page]

WO2004098494A3 - Compounds, compositions, and methods - Google Patents

Compounds, compositions, and methods Download PDF

Info

Publication number
WO2004098494A3
WO2004098494A3 PCT/US2004/011267 US2004011267W WO2004098494A3 WO 2004098494 A3 WO2004098494 A3 WO 2004098494A3 US 2004011267 W US2004011267 W US 2004011267W WO 2004098494 A3 WO2004098494 A3 WO 2004098494A3
Authority
WO
WIPO (PCT)
Prior art keywords
compositions
compounds
methods
fungal
kip1
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/US2004/011267
Other languages
French (fr)
Other versions
WO2004098494A2 (en
Inventor
Adam Tomasi
Bradley P Morgan
Jr David J Morgans
Andrew Mcdonald
David Roof
Mary Maxon
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Cytokinetics Inc
Original Assignee
Cytokinetics Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Cytokinetics Inc filed Critical Cytokinetics Inc
Priority to EP04750041A priority Critical patent/EP1620413A2/en
Publication of WO2004098494A2 publication Critical patent/WO2004098494A2/en
Publication of WO2004098494A3 publication Critical patent/WO2004098494A3/en
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/18—Benzimidazoles; Hydrogenated benzimidazoles with aryl radicals directly attached in position 2
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D235/00—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings
    • C07D235/02—Heterocyclic compounds containing 1,3-diazole or hydrogenated 1,3-diazole rings, condensed with other rings condensed with carbocyclic rings or ring systems
    • C07D235/04—Benzimidazoles; Hydrogenated benzimidazoles
    • C07D235/24—Benzimidazoles; Hydrogenated benzimidazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D235/30—Nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D277/00—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings
    • C07D277/60—Heterocyclic compounds containing 1,3-thiazole or hydrogenated 1,3-thiazole rings condensed with carbocyclic rings or ring systems
    • C07D277/62—Benzothiazoles
    • C07D277/68—Benzothiazoles with hetero atoms or with carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals, directly attached in position 2
    • C07D277/82—Nitrogen atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)

Abstract

Substituted indoles useful for treating fungal infections by modulating the activity of the fungal kinesin Kip1 are disclosed.
PCT/US2004/011267 2003-04-30 2004-04-29 Compounds, compositions, and methods Ceased WO2004098494A2 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
EP04750041A EP1620413A2 (en) 2003-04-30 2004-04-29 Compounds, compositions, and methods

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
US46716503P 2003-04-30 2003-04-30
US46697303P 2003-04-30 2003-04-30
US60/467,165 2003-04-30
US60/466,973 2003-04-30

Publications (2)

Publication Number Publication Date
WO2004098494A2 WO2004098494A2 (en) 2004-11-18
WO2004098494A3 true WO2004098494A3 (en) 2005-03-24

Family

ID=33436714

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/US2004/011267 Ceased WO2004098494A2 (en) 2003-04-30 2004-04-29 Compounds, compositions, and methods

Country Status (2)

Country Link
EP (1) EP1620413A2 (en)
WO (1) WO2004098494A2 (en)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ES2524803T3 (en) 2002-12-19 2014-12-12 The Scripps Research Institute Compositions and methods to stabilize transthyretin and inhibit the abnormal folding of transthyretin
CA2534649A1 (en) 2003-08-01 2005-02-10 Genelabs Technologies, Inc. Bicyclic imidazol derivatives against flaviviridae
GB0401334D0 (en) * 2004-01-21 2004-02-25 Novartis Ag Organic compounds
US20050261365A1 (en) 2004-05-20 2005-11-24 The Scripps Research Institute Transthyretin stabilization
US7728026B2 (en) 2005-04-11 2010-06-01 Abbott Laboratories, Inc. 2-substituted-1 h-benzimidazile-4-carboxamides are PARP inhibitors
TWI375673B (en) 2005-04-11 2012-11-01 Abbott Lab 1h-benzimidazole-4-carboxamides substituted with a quaternary carbon at the 2-position are potent parp inhibitors
US7906522B2 (en) 2005-04-28 2011-03-15 Kyowa Hakko Kirin Co., Ltd 2-aminoquinazoline derivatives
JP2008543915A (en) 2005-06-21 2008-12-04 ノイロサーチ アクティーゼルスカブ 2- (Phenylamino) benzimidazole derivatives and their use as modulators of low conductance calcium-dependent potassium channels
JPWO2007020936A1 (en) 2005-08-17 2009-02-26 第一三共株式会社 Antifungal bicyclic heterocyclic compound
ES2342007T3 (en) 2005-11-15 2010-06-30 Abbott Laboratories 1H-BENZIMIDAZOL-4-EFFECTIVE REPLACED CARBOXAMIDS AS INHIBITORS OF (PARP).
SI1986633T1 (en) 2006-02-10 2015-03-31 Summit Corporation Plc Treatment of duchenne muscular dystrophy
JP5228237B2 (en) 2006-05-02 2013-07-03 アボット・ラボラトリーズ Substituted 1H-benzimidazole-4-carboxamide is a potent PARP inhibitor
AR063311A1 (en) 2006-10-18 2009-01-21 Novartis Ag ORGANIC COMPOUNDS
US8067613B2 (en) 2007-07-16 2011-11-29 Abbott Laboratories Benzimidazole poly(ADP ribose)polymerase inhibitors
ES2401557T3 (en) 2007-08-02 2013-04-22 Amgen, Inc Modulators of Pl3 kinases and methods of use
SI2170396T1 (en) 2007-08-03 2017-04-26 Summit (Oxford) Limited Drug combinations for the treatment of duchenne muscular dystrophy
CA2710194C (en) 2007-12-19 2014-04-22 Amgen Inc. Inhibitors of p13 kinase
EP2247600A4 (en) 2008-02-06 2011-09-14 Biomarin Pharm Inc INHIBITORS BASED ON BENZOXAZOLE-CARBOXAMIDE COMPOUNDS OF POLY (ADP-RIBOSE) POLYMERASE (PARP) ACTIVITY
EP2269993B1 (en) 2008-04-23 2013-02-27 Kyowa Hakko Kirin Co., Ltd. 2-aminoquinazoline derivative
AU2009248774B2 (en) 2008-05-23 2012-05-31 Novartis Ag Derivatives of quinolines and quinoxalines as protein tyrosine kinase inhibitors
TW201000099A (en) 2008-06-20 2010-01-01 Amgen Inc S1P1 receptor agonists and use thereof
WO2010083199A1 (en) 2009-01-19 2010-07-22 Abbott Laboratories Benzthiazole inhibitors of poly(adp-ribose)polymerase
WO2010133534A1 (en) * 2009-05-19 2010-11-25 Cellzome Limited Bicyclic amino substituted compounds as pi3k inhibitors
GB201007286D0 (en) 2010-04-30 2010-06-16 Astex Therapeutics Ltd New compounds
US20130196990A1 (en) 2010-10-06 2013-08-01 Junya Qu Benzimidazole Derivatives As PI3 Kinase Inhibitors
GB201020179D0 (en) 2010-11-29 2011-01-12 Astex Therapeutics Ltd New compounds
KR20140054231A (en) 2011-09-16 2014-05-08 화이자 인코포레이티드 Solid forms of a transthyretin dissociation inhibitor
GB201118656D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118675D0 (en) 2011-10-28 2011-12-14 Astex Therapeutics Ltd New compounds
GB201118654D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201118652D0 (en) 2011-10-28 2011-12-07 Astex Therapeutics Ltd New compounds
GB201209609D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
GB201209613D0 (en) 2012-05-30 2012-07-11 Astex Therapeutics Ltd New compounds
TWI530499B (en) 2013-03-28 2016-04-21 吉李德科學股份有限公司 Benzimidazolone derivatives as bromodomain inhibitors
GB201307577D0 (en) 2013-04-26 2013-06-12 Astex Therapeutics Ltd New compounds
TWI527811B (en) 2013-05-09 2016-04-01 吉李德科學股份有限公司 Benzimidazole derivatives as bromodomain inhibitors
EP3010918B1 (en) 2013-06-21 2018-08-15 Zenith Epigenetics Ltd. Novel substituted bicyclic compounds as bromodomain inhibitors
SI3010503T1 (en) 2013-06-21 2020-07-31 Zenith Epigenetics Ltd. Novel bicyclic bromodomain inhibitors
JP6542212B2 (en) 2013-07-31 2019-07-10 ゼニス・エピジェネティクス・リミテッドＺｅｎｉｔｈ Ｅｐｉｇｅｎｅｔｉｃｓ Ｌｔｄ． Novel quinazolinones as bromodomain inhibitors
US9108953B2 (en) 2013-11-26 2015-08-18 Gilead Sciences, Inc. Quinoline derivatives as bromodomain inhibitors
JO3512B1 (en) 2014-03-26 2020-07-05 Astex Therapeutics Ltd Quinoxaline derivatives useful as fgfr kinase modulators
HUE053653T2 (en) 2014-03-26 2021-07-28 Astex Therapeutics Ltd Combinations of FGFR inhibitor and IGF1R inhibitor
RU2715236C2 (en) 2014-03-26 2020-02-26 Астекс Терапьютикс Лтд Combinations
HK1246273B (en) 2014-12-01 2019-12-06 恒翼生物医药(上海)股份有限公司 Substituted pyridines as bromodomain inhibitors
CA2966449A1 (en) 2014-12-11 2016-06-16 Zenith Epigenetics Ltd. Substituted heterocycles as bromodomain inhibitors
EP3233846A4 (en) 2014-12-17 2018-07-18 Zenith Epigenetics Ltd. Inhibitors of bromodomains
JOP20200201A1 (en) 2015-02-10 2017-06-16 Astex Therapeutics Ltd Pharmaceutical compositions comprising n-(3,5-dimethoxyphenyl)-n'-(1-methylethyl)-n-[3-(1-methyl-1h-pyrazol-4-yl)quinoxalin-6-yl]ethane-1,2-diamine
US10478494B2 (en) 2015-04-03 2019-11-19 Astex Therapeutics Ltd FGFR/PD-1 combination therapy for the treatment of cancer
ES2904513T3 (en) 2015-09-23 2022-04-05 Janssen Pharmaceutica Nv Biheteroaryl substituted 1,4-benzodiazepines and uses thereof for the treatment of cancer
EP3353177B1 (en) 2015-09-23 2020-06-03 Janssen Pharmaceutica NV Tricyclic heterocycles for the treatment of cancer
EP4349834A4 (en) * 2021-06-02 2024-10-16 Nihon Nohyaku Co., Ltd. BENZIMIDAZOLE COMPOUND OR SALT THEREOF, AGENT FOR COMBATING DIROFILARIASIS WITH SAID COMPOUND AND METHOD OF USE THEREOF
AU2022306297A1 (en) 2021-07-09 2024-02-08 Plexium, Inc. Aryl compounds and pharmaceutical compositions that modulate ikzf2

Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795903A (en) * 1994-10-26 1998-08-18 Rhone-Poulenc Rorer S.A. 6-polyfluoroalkoxy-and 6-polyfluoroalkyl-2-aminobenzothiazole derivatives

Patent Citations (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5795903A (en) * 1994-10-26 1998-08-18 Rhone-Poulenc Rorer S.A. 6-polyfluoroalkoxy-and 6-polyfluoroalkyl-2-aminobenzothiazole derivatives

Also Published As

Publication number Publication date
WO2004098494A2 (en) 2004-11-18
EP1620413A2 (en) 2006-02-01

Similar Documents

Publication Publication Date Title
WO2004098494A3 (en) Compounds, compositions, and methods
WO2004018058A3 (en) Compounds, compositions, and methods
WO2006086562A3 (en) Phenylazetidinone derivatives
WO2005030791A3 (en) Isoquinolinone potassium channel inhibitors
WO2006060535A3 (en) Indole derivatives for use as ppar active compounds
WO2003048081A3 (en) Glycinamides as factor xa inhibitors
WO2005030129A3 (en) Quinoline potassium channel inhibitors
WO2003094839A8 (en) Pyrimidinone compounds, compositions and methods
WO2006060456A3 (en) Indole derivatives for use as ppar ppar active compounds
WO2005042497A3 (en) Benzimidazoles useful as modulators of ion channels
WO2003088903A3 (en) Compounds, compositions, and methods
WO2006078287A3 (en) Pde4b inhibitors and uses therefor
WO2006113432A3 (en) Compounds, compositions and methods
WO2005046578A3 (en) Isoquinolinone potassium channel inhibitors
WO2004009036A3 (en) Compounds compositions and methods
WO2005021544A3 (en) N3-substituted imidazopyridine-derivatives as c-kit inhibitors
WO2005030130A3 (en) Isoquinoline potassium channel inhibitors
WO2008051197A3 (en) Small-molecule botulinum toxin inhibitors
WO2004034972A3 (en) Compounds, compositions, and methods
WO2004064741A3 (en) Compounds, compositions, and methods
WO2005033112A3 (en) Substituted indole derivatives
WO2004006865A3 (en) Compounds, compositions, and methods
WO2005000208A3 (en) Combination therapy for the treatment of neoplasms
WO2004026226A3 (en) Compounds, compositions and methods
WO2004032840A3 (en) Compounds, compositions, and methods

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A2

Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BW BY BZ CA CH CN CO CR CU CZ DE DK DM DZ EC EE EG ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NA NI NO NZ OM PG PH PL PT RO RU SC SD SE SG SK SL SY TJ TM TN TR TT TZ UA UG US UZ VC VN YU ZA ZM ZW

AL Designated countries for regional patents

Kind code of ref document: A2

Designated state(s): BW GH GM KE LS MW MZ NA SD SL SZ TZ UG ZM ZW AM AZ BY KG KZ MD RU TJ TM AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IT LU MC NL PL PT RO SE SI SK TR BF BJ CF CG CI CM GA GN GQ GW ML MR NE SN TD TG

121 Ep: the epo has been informed by wipo that ep was designated in this application
WWE Wipo information: entry into national phase

Ref document number: 2004750041

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 2004750041

Country of ref document: EP

WWP Wipo information: published in national office

Ref document number: 2004750041

Country of ref document: EP